Compare PKBK & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PKBK | MDWD |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.2M | 238.5M |
| IPO Year | N/A | 2014 |
| Metric | PKBK | MDWD |
|---|---|---|
| Price | $24.85 | $18.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 39.5K | ★ 82.4K |
| Earning Date | 01-23-2026 | 11-20-2025 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 21.56 | N/A |
| EPS | ★ 2.83 | N/A |
| Revenue | ★ $71,766,000.00 | $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | N/A | $25.33 |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | ★ 13.64 | 6.15 |
| 52 Week Low | $16.94 | $14.14 |
| 52 Week High | $25.77 | $22.51 |
| Indicator | PKBK | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 64.95 | 57.39 |
| Support Level | $24.56 | $18.55 |
| Resistance Level | $25.70 | $18.96 |
| Average True Range (ATR) | 0.46 | 0.53 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 54.77 | 49.21 |
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.